US free shipping over $150 · Exact worldwide rate at checkout · Crypto-only checkout guide — Shop now
T
Titan PeptideResearch-grade nasal sprays

Retatrutide · cycle length · research use only

How long is a retatrutide cycle? Why a triple agonist isn't 'cycled' like a repair peptide.

Search 'retatrutide cycle length' and you'll find the same on/off framing people apply to BPC-157 or a growth-hormone secretagogue — run it for X weeks, then take a break. For a GLP-1/GIP/glucagon triple agonist that framing is a category error. The metabolic-agonist trials didn't cycle at all: retatrutide's Phase 2 obesity study (Jastreboff et al., NEJM 2023) dosed participants continuously for 48 weeks and reported ~24% mean weight loss at the top dose — a continuous escalation, never an on-then-off block. And the single most consistent published finding across this entire drug class is what happens when treatment STOPS: substantial weight regain. When tirzepatide was withdrawn in SURMOUNT-4, participants regained ~14% over the following year while those who continued lost a further ~6.7%; a year after stopping semaglutide in the STEP 1 extension, roughly two-thirds of the lost weight had returned. That is why the trialists describe obesity as a chronic condition needing long-term therapy — the opposite of a 'cycle it and rest' model. This page lays out what the research actually establishes, why the cycling concept doesn't transfer here, and the one genuine schedule that does exist: the multi-month titration ramp. It is a research reference summarising published trial data and pharmacology — not a human-use schedule, not dosing or medical advice.

Retatrutide — $199.99Retatrutide dosage & titration

'Cycling' is a bodybuilding-peptide concept — it doesn't transfer here

The on/off cycling idea comes from repair and growth-hormone peptides, where the rationale is either caution (no long-term human data) or a genuine kinetic driver (pulsing a GH secretagogue to preserve receptor responsiveness). An incretin agonist has neither of those as a reason to schedule breaks. In the metabolic-agonist literature the drugs are studied as continuous therapy, and importing a 'weeks on, weeks off' block from a different peptide class onto retatrutide misreads what the compound is and how it was actually trialled.

How repair-peptide cycling differs →

The Phase 2 trial ran continuously for 48 weeks

Retatrutide's pivotal Phase 2 obesity study (Jastreboff et al., New England Journal of Medicine, 2023) escalated the dose over months and continued dosing to week 48, reporting up to ~24% mean body-weight reduction at the highest dose — with the curve still trending down at study end. There was no on/off cycling arm. Reading a fixed trial duration as a 'recommended cycle length' repeats the same mistake the preclinical peptide pages make: a study endpoint is not a schedule.

The 48-week response curve →

The defining finding is weight regain after stopping

The most consistent published result for this drug class is what happens on discontinuation. In SURMOUNT-4 (Aronne et al., JAMA 2024), withdrawing tirzepatide after a 36-week lead-in was followed by ~14% weight regain over the next 52 weeks, while continuation added ~6.7% further loss. In the STEP 1 extension (Wilding et al., 2022), participants regained roughly two-thirds of their lost weight within a year of stopping semaglutide. A 2025 BMJ meta-analysis put regain at ~60% of lost weight by one year across liraglutide, semaglutide and tirzepatide. The pattern is class-wide — the reason these agents aren't cycled.

Adverse-event profile →

Why trialists call it chronic therapy, not a cycle

The SURMOUNT-4 authors concluded that the consistency of post-cessation regain across more than two decades of weight-management trials 'suggests that obesity is a chronic metabolic condition… requiring long-term therapy in most patients.' That is the published position on duration for this class: continuous treatment to maintain the effect, not a fixed run followed by a planned break. Any page presenting retatrutide as a compound you 'cycle off' is applying a framework the trial evidence points away from.

Retatrutide vs semaglutide →

The one genuine schedule: the titration ramp

The closest thing retatrutide has to a 'schedule' is dose escalation, not a cycle. Phase 2 stepped the weekly dose up gradually over months to reach the higher targets — a ramp designed to limit gastrointestinal side effects, which cluster during escalation. That is a real, published structure worth understanding, and it's an ascending ladder rather than an on/off loop. The dosage page walks through the titration steps and the reconstitution math that sets each week's draw volume.

Titration ladder & recon math →

Research-use framing

Everything here summarises published clinical-trial designs and pharmacology reproduced as a research reference for laboratory and in-vitro modelling — not instructions for human use, and not a claim of efficacy or an optimal schedule in people. Retatrutide is an investigational compound without regulatory approval as a therapeutic. Titan supplies it strictly as a research reagent, not for human or animal consumption, and nothing on this page is medical or dosing advice.

Lab testing & COA workflow →

The detail, in plain terms

Retatrutide 'cycle length', separated into evidence and assumption.

A plain-terms split between what the metabolic-agonist trials actually establish about retatrutide duration and the on/off 'cycle' assumptions imported from unrelated peptide classes. The trial figures are continuous-treatment and post-cessation data; the 'cycle' figures have no controlled-trial basis for this drug class. Reproduced as a research reference, not a human-use schedule.

Validated 'cycle length'
None. No trial of retatrutide (or the incretin-agonist class) tested an on/off cycle. The drugs were studied as continuous therapy.
Phase 2 trial duration
48 weeks continuous dosing (Jastreboff et al., NEJM 2023); ~24% mean weight loss at the top dose, curve still declining at week 48.
On discontinuation (tirzepatide)
SURMOUNT-4 (Aronne et al., JAMA 2024): ~14% weight regain over 52 weeks after withdrawal vs ~6.7% further loss with continuation.
On discontinuation (semaglutide)
STEP 1 extension (Wilding et al., 2022): ~two-thirds of lost weight regained within ~52 weeks of stopping.
Class-wide regain estimate
~60% of lost weight regained by one year, plateauing near 60 weeks (BMJ 2025 meta-analysis; liraglutide/semaglutide/tirzepatide).
Trialists' stated model
Chronic condition requiring long-term therapy — continuous treatment to maintain effect, explicitly not an on/off cycle.
The real schedule that exists
Dose titration: a gradual multi-month escalation to limit GI effects during ramp-up — an ascending ladder, not a cycle.
Reason peptides get cycled (for contrast)
Repair peptides: caution (no long-term data). GH secretagogues: receptor resensitisation. Retatrutide has neither driver.

Questions researchers ask

Before you order.

How long should a retatrutide cycle be?
The premise doesn't fit the drug. Retatrutide is a GLP-1/GIP/glucagon triple agonist, and the metabolic-agonist trials did not use on/off cycles — its Phase 2 study (NEJM 2023) dosed continuously for 48 weeks. There is no research-validated 'cycle length' because the class isn't cycled; it's studied as continuous therapy. Any specific 'X weeks on, then off' figure you see for retatrutide is imported from repair or growth-hormone peptides and has no controlled-trial basis for this compound. This page is a research reference summarising that evidence, not a human-use schedule.
Do you have to cycle off retatrutide?
The trial evidence points the other way. The most consistent published finding across this drug class is that stopping leads to substantial weight regain — about 14% over a year after tirzepatide withdrawal in SURMOUNT-4, and roughly two-thirds of lost weight within a year of stopping semaglutide in the STEP 1 extension. The SURMOUNT-4 authors concluded obesity behaves as a chronic condition requiring long-term therapy. So in the research context these agents are framed as continuous rather than cycled. Nothing here is medical advice; it summarises what the trials reported.
Why is retatrutide not cycled like BPC-157 or CJC-1295/ipamorelin?
Because the reasons those peptides are cycled don't apply. BPC-157's cycling convention rests on the absence of long-term human safety data (a caution argument), and growth-hormone secretagogues like CJC-1295/ipamorelin are pulsed to preserve pituitary receptor responsiveness (a mechanism-based driver). A triple incretin agonist has neither — no demonstrated desensitisation requiring breaks, and it was trialled as continuous therapy. Same word, 'cycle', but a completely different underlying logic, which is why the on/off framing transfers poorly.
Is there any real 'schedule' for retatrutide?
Yes — but it's titration, not a cycle. The Phase 2 study escalated the weekly dose gradually over several months to reach the higher targets, a ramp designed to limit the gastrointestinal side effects that cluster during dose escalation. That is an ascending ladder with a defined structure, not an on-then-off loop. The dosage page covers the titration steps and the reconstitution math that determines each week's draw volume.
Is retatrutide approved for human use?
No. Retatrutide is an investigational compound still in clinical trials, without regulatory approval as a therapeutic. Titan Peptide Lab supplies it strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption, and not for diagnostic, therapeutic or preventative use. The duration and cycling information on this page summarises published trial data and is a research reference, not medical or dosing advice.

Related reading

Before you check out.